# Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)

> **NCT01496053** · PHASE2,PHASE3 · COMPLETED · sponsor: **Oslo University Hospital** · enrollment: 100 (actual)

## Conditions studied

- Ulcerative Colitis
- Crohn's Disease
- Inflammatory Bowel Disease

## Interventions

- **DIETARY_SUPPLEMENT:** AndoSan
- **DIETARY_SUPPLEMENT:** Sugar Extract

## Key facts

- **NCT ID:** NCT01496053
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2015-12
- **Final completion:** 2016-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01496053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01496053, "Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01496053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*